42.98 USD
+0.15 (+0.35%)
42.99 USD
+0.01 (+0.02%)
Overall SRDX gets a fundamental rating of 3 out of 10. We evaluated SRDX against 188 industry peers in the Health Care Equipment & Supplies industry. While SRDX seems to be doing ok healthwise, there are quite some concerns on its profitability. SRDX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SRDX had negative earnings in the past year.
In the past year SRDX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: SRDX reported negative net income in multiple years.
Of the past 5 years SRDX 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -10.38%, SRDX is in the better half of the industry, outperforming 60.11% of the companies in the same industry.
SRDX has a better Return On Equity (-15.84%) than 62.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.38% | ||
| ROE | -15.84% | ||
| ROIC | N/A |
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 73.09%, SRDX belongs to the best of the industry, outperforming 82.98% of the companies in the same industry.
SRDX's Gross Margin has declined in the last couple of years.
SRDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
2. Health
2.1 Basic Checks
SRDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRDX has been increased compared to 1 year ago.
SRDX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRDX has a worse debt to assets ratio.
2.2 Solvency
SRDX has an Altman-Z score of 7.89. This indicates that SRDX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.89, SRDX belongs to the best of the industry, outperforming 86.70% of the companies in the same industry.
SRDX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
SRDX has a Debt to Equity ratio of 0.27. This is comparable to the rest of the industry: SRDX outperforms 54.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.89 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
SRDX has a Current Ratio of 3.91. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.91, SRDX is doing good in the industry, outperforming 69.15% of the companies in the same industry.
A Quick Ratio of 3.10 indicates that SRDX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.10, SRDX is in the better half of the industry, outperforming 68.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
SRDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -172.73%.
SRDX shows a decrease in Revenue. In the last year, the revenue decreased by -0.02%.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)-172.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.22%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-2.55%
3.2 Future
SRDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.04% yearly.
Based on estimates for the next years, SRDX will show a small growth in Revenue. The Revenue will grow by 1.78% on average per year.
EPS Next Y10.36%
EPS Next 2Y18.73%
EPS Next 3Y42.04%
EPS Next 5YN/A
Revenue Next Year-4.48%
Revenue Next 2Y-0.63%
Revenue Next 3Y1.78%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SRDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRDX is valued a bit cheaper than 63.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 86.22 |
4.3 Compensation for Growth
SRDX's earnings are expected to grow with 42.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.73%
EPS Next 3Y42.04%
5. Dividend
5.1 Amount
No dividends for SRDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.98
+0.15 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners90.7%
Inst Owner Change-6.06%
Ins Owners3.36%
Ins Owner Change-247.34%
Market Cap614.61M
Revenue(TTM)120.80M
Net Income(TTM)-17.63M
Analysts45.71
Price Target43.86 (2.05%)
Short Float %3.34%
Short Ratio0.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.5%
Min EPS beat(2)-12.46%
Max EPS beat(2)131.46%
EPS beat(4)3
Avg EPS beat(4)60.58%
Min EPS beat(4)-12.46%
Max EPS beat(4)131.46%
EPS beat(8)7
Avg EPS beat(8)83.05%
EPS beat(12)11
Avg EPS beat(12)135.86%
EPS beat(16)15
Avg EPS beat(16)112.5%
Revenue beat(2)1
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)3.32%
Revenue beat(4)2
Avg Revenue beat(4)-4.04%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)7.17%
Revenue beat(8)5
Avg Revenue beat(8)-0.37%
Revenue beat(12)9
Avg Revenue beat(12)3.53%
Revenue beat(16)11
Avg Revenue beat(16)2.67%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.52 | ||
| P/tB | 14.17 | ||
| EV/EBITDA | 86.22 |
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS8.45
BVpS7.78
TBVpS3.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.38% | ||
| ROE | -15.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.09% | ||
| FCFM | N/A |
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
F-Score2
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.23 | ||
| Cap/Depr | 19.66% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 7.89 |
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)37.09%
Cap/Depr(5y)48.03%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-172.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.22%
EPS Next Y10.36%
EPS Next 2Y18.73%
EPS Next 3Y42.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-2.55%
Revenue Next Year-4.48%
Revenue Next 2Y-0.63%
Revenue Next 3Y1.78%
Revenue Next 5YN/A
EBIT growth 1Y68.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200.15%
EBIT Next 3Y61.42%
EBIT Next 5YN/A
FCF growth 1Y-188.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-127.84%
OCF growth 3Y-74.74%
OCF growth 5Y-50.13%
SURMODICS INC / SRDX FAQ
What is the fundamental rating for SRDX stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRDX.
Can you provide the valuation status for SURMODICS INC?
ChartMill assigns a valuation rating of 1 / 10 to SURMODICS INC (SRDX). This can be considered as Overvalued.
How profitable is SURMODICS INC (SRDX) stock?
SURMODICS INC (SRDX) has a profitability rating of 3 / 10.
What is the financial health of SURMODICS INC (SRDX) stock?
The financial health rating of SURMODICS INC (SRDX) is 5 / 10.